Affimed Stock (NASDAQ:AFMD)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$3.26

52W Range

$2.92 - $8.95

50D Avg

$3.57

200D Avg

$4.93

Market Cap

$49.79M

Avg Vol (3M)

$79.27K

Beta

2.10

Div Yield

-

AFMD Company Profile


Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

DE

Employees

76

IPO Date

Sep 12, 2014

Website

AFMD Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Collaboration€7.76M€41.20M€39.30M
Service€510.00K€155.00K€1.06M

Fiscal year ends in Dec 23 | Currency in EUR

AFMD Financial Summary


Dec 23Dec 22Dec 21
Revenue€8.28M€41.35M€40.37M
Operating Income€-106.66M€-88.12M€-64.03M
Net Income€-105.94M€-86.00M€-57.52M
EBITDA€-103.81M€-86.64M€-64.01M
Basic EPS-€-0.60€-0.48
Diluted EPS-€-0.60€-0.48

Fiscal year ends in Dec 23 | Currency in EUR

Latest Earnings Call Transcripts


Q2 24Sep 05, 24 | 11:17 AM
Q1 24Jun 12, 24 | 10:48 AM
Q4 23Mar 28, 24 | 12:04 PM

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
MREOMereo BioPharma Group plc
ADCTADC Therapeutics SA
DAWNDay One Biopharmaceuticals, Inc.
PDSBPDS Biotechnology Corporation
ADAPAdaptimmune Therapeutics plc
CRVSCorvus Pharmaceuticals, Inc.
APTOAptose Biosciences Inc.
TERNTerns Pharmaceuticals, Inc.
INZYInozyme Pharma, Inc.
AGENAgenus Inc.
EFTReFFECTOR Therapeutics, Inc.
PIRSPieris Pharmaceuticals, Inc.
LPTXLeap Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
ELEVElevation Oncology, Inc.